Related Experiment Video
Updated: Aug 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumonia: the impact of antibiotic resistance on its management
1Department of Microbiology and Infectious Diseases, City Hospital, Nottingham, U.K.
Abstract:
Pneumonia in the community affects between 1 and 5 per 1000 per year. The microbial aetiology is diverse and influenced by preexisting disease, seasonality, as well as animate and inanimate environmental sources; pneumococci, Legionella spp., Mycoplasma pneumoniae, and more recently Chlamydia pneumoniae are the predominant bacterial pathogens. Gram-negative enteric bacteria although less common are particularly virulent. Antibiotic resistance is well established for Haemophilus influenzae and Gram-negative bacillary infections, but has been a recent phenomenon in the case of Streptococcus pneumoniae, which is numerically the leading pathogen. Despite the concerns raised by this reduced susceptibility to penicillin, evidence that this has been translated into increased clinical failures is currently difficult to establish. Macrolide and tetracycline resistance among pneumococci is more common. beta-Lactamase production by H. influenzae has now reached levels where, in those with severe pneumonia, beta-lactamase stable agents are preferred. Consensus Guidelines on the treatment of community acquired pneumonia have been published by the British Thoracic Society, the American Thoracic Society, and from Expert Panels in Canada and France. These emphasize severity assessment and differentiate management in the community or hospital setting. The recommended regimens are compared and contrasted. In conclusion, mild/moderate pneumonia, when pneumococcal in nature, is likely to still respond to amoxycillin or penicillin G, but in higher dosages where pneumococcal resistance is documented. However, in severe infection where pneumococcal resistance, other beta-lactamase-producing pathogens, or an atypical infection could be operating, it is important that initial empirical therapy be broad spectrum and promptly administered. Treating multiresistant pneumococcal disease in those allergic to beta-lactams presents a particular dilemma. Glycopeptides are currently preferred.
Insights
Community-acquired pneumonia has diverse causes, with increasing antibiotic resistance in key pathogens like Streptococcus pneumoniae. Current guidelines recommend broad-spectrum antibiotics for severe cases and specific treatments for resistant strains.
Area of Science:
- Infectious Diseases
- Microbiology
- Pulmonology
Background:
- Community-acquired pneumonia (CAP) affects 1-5 per 1000 individuals annually, with varied microbial origins.
- Predominant bacterial pathogens include pneumococci, Legionella spp., Mycoplasma pneumoniae, and Chlamydia pneumoniae.
- Gram-negative enteric bacteria, though less common, present significant virulence and established antibiotic resistance.
Purpose of the Study:
- To review the microbial etiology of CAP and the growing challenge of antibiotic resistance.
- To compare and contrast current international consensus guidelines for CAP management.
- To discuss optimal treatment strategies based on disease severity and pathogen resistance.
Main Methods:
- Literature review of CAP etiology, focusing on predominant pathogens and resistance patterns.
- Analysis of antibiotic resistance trends, particularly in Streptococcus pneumoniae and Haemophilus influenzae.
- Comparison of treatment recommendations from major international respiratory societies and expert panels.
Main Results:
- Antibiotic resistance is increasing in Streptococcus pneumoniae, a leading CAP pathogen, though clinical impact is still being established.
- Haemophilus influenzae exhibits high levels of beta-lactamase production, necessitating beta-lactamase stable agents for severe pneumonia.
- Macrolide and tetracycline resistance are more prevalent among pneumococci.
Conclusions:
- Mild/moderate pneumococcal pneumonia may respond to high-dose amoxicillin or penicillin G if resistance is documented.
- Severe CAP requires prompt, broad-spectrum empirical therapy to cover resistant pathogens and atypical infections.
- Managing beta-lactam-allergic patients with multidrug-resistant pneumococcal disease poses a challenge, with glycopeptides as a preferred option.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanism of Antibiotic Resistance in MRSA
Pneumonia I: Introduction